Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 0.61 |
| ▸ | CTSD | P07339 | 1/20 | 0.61 |
| ▸ | PLAU | P00749 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9932 | 0.81 | BACE1 (0.59) | BACE1CTSDRAB9ASLC6A2SLC6A4 | |
| SCHEMBL30838469 | 0.78 | MCL1 (0.66) | RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL84188 | 0.78 | SLC6A2 (0.66) | RAB9ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL30610922 | 0.78 | SLC6A2 (0.66) | RAB9ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL29618929 | 0.78 | SLC6A2 (0.66) | RAB9ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL8691 | 0.77 | ALOX5AP (0.52) | BACE1CTSD | |
| Bromide SCHEMBL7032662 | 0.77 | SLC6A2 (0.64) | RAB9ASLC6A2SLC6A4SLC6A3MEN1 | |
| SCHEMBL22926832 | 0.76 | BACE1 (1.00) | BACE1CTSDPLAUNCF1NOS2 | |
| SCHEMBL4756382 | 0.76 | DHFR (0.52) | — | |
| SCHEMBL1767713 | 0.76 | BACE1 (1.00) | BACE1CTSDPLAUACHENCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | BACE1 1/4885CTSD 827/4885PLAU 2335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.